West China Journal of Stomatology ›› 2022, Vol. 40 ›› Issue (6): 704-709.doi: 10.7518/hxkq.2022.06.012

Previous Articles     Next Articles

Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma

Yue Qiangwei(), Xu Le, Zhang Dongsheng.()   

  1. Dept. of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
  • Received:2022-02-21 Revised:2022-09-08 Online:2022-12-01 Published:2022-11-23
  • Contact: Zhang Dongsheng. E-mail:32161343@qq.com;ds63zhang@sdu.edu.cn
  • Supported by:
    Shandong Provincial Natural Science Foundation(ZR2021MH353);Correspondence: Zhang Dongsheng, E-mail: ds63zhang@sdu.edu.cn


Objective This work aimed to construct N6-methyladenosine (m6A) regulator-based prognostic signature and evaluate the prognostic value and the intervention on tumor immune microenvironment of this m6A risk signature. Methods Using transcriptome and clinical data of head and neck squamous cell carcinoma (HNSCC) from The Cancer Genome Atlas (TCGA), we profiled m6A regulators and constructed an m6A risk signature. The relationship between m6A modulation and immune function was studied by differential gene expression, cell type enrichment, and correlation analyses. Results Fifteen m6A regulators had aberrant expression in HNSCC. A three-gene m6A prognostic signature (i.e., YTHDC2, IGF2BP2, and HNRNPC) was constructed and identified as an independent prognostic indicator for HNSCC. The m6A regulator signature-based high-risk group revealed pro-tumoral immune microenvironment due to the dysregulation of immune-related gene expression, abnormal enrichment of multiple immunocytes, and production of immunoregulatory factors. Conclusion This comprehensive analysis of m6A regulators and tumor immune landscape in HNSCC revealed that the m6A signature of YTHDC2, IGF2BP2, and HNRNPC could serve as a promising biomarker for monitoring HNSCC development and may be a potential target for tumor therapy in the future.

Key words: head and neck squamous cell carcinoma, N6-methyladenosine, prognostic risk signature, tumor immune microenvironment, bioinformatic analysis

CLC Number: